BioSpace News Archive

PreciseDx, the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, today announced the appointment of Molly Harper, Chief Business Officer for Synlogic, Inc., and Eric Converse, the Chief Executive Officer at AMRA Medical, to the Company’s Board of Directors.

Bearpac Medical, LLC announced that its Passio Pump Drainage System has received an Innovative Technology contract from Vizient, Inc. the nation’s largest member-driven health care performance improvement company.

Exome Asset Management LLC, led by Sam Isaly, participated in the Series D1 financing of IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, which recently closed.

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, announced publication of a peer-review scientific article in the Journal of Medical Virology on the anti-coronavirus properties of Brilacidin.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for QRX003.

The National Comprehensive Cancer Network® announced the publication of new expert consensus recommendations to address routine problems that can occur during prescribing, receiving, storing, preparing, and delivering investigational drugs.

BodiMetrics announced today the results of a 164 patient clinical study that compared their Prevention circul+ wearable ring device versus traditional polysomnography (PSG) test.

Rehabtronics is pleased to announce that Genome BC is providing $1.25 million to support commercialization of Prelivia, the world’s first neuroscience-based technology designed to protect patients against deadly pressure injuries.

Allergan, an AbbVie company, announced that LASTACAFT® is now available without a prescription for the estimated 40% of Americans1 who live with ocular allergies.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2021 fourth quarter and full year financial results after the market closes on Tuesday, March 29, 2022.